A Phase 1, Randomized, 2-way Crossover, Food-effect Study of Ecopipam Pharmacokinetics After Administration of the To Be Marketed Tablet in Healthy Subjects
Latest Information Update: 29 Jan 2025
At a glance
- Drugs Ecopipam (Primary)
- Indications Cardiovascular disorders; Gilles de la Tourette's syndrome; Lesch-Nyhan syndrome; Restless legs syndrome; Speech disorders
- Focus Pharmacokinetics
- Sponsors Emalex Biosciences
Most Recent Events
- 27 Jan 2025 Status changed from active, no longer recruiting to completed.
- 24 Dec 2024 Planned End Date changed from 22 Dec 2024 to 27 Dec 2024.
- 24 Dec 2024 Status changed from not yet recruiting to active, no longer recruiting.